Chew V - Search Results

1

Detection, enumeration, and characterization of immune cells infiltrating melanoma tumors.

Toh B, Nardin A, Dai X, Keeble J, Chew V, Abastado JP. Toh B, et al. Among authors: chew v. Methods Mol Biol. 2013;961:261-77. doi: 10.1007/978-1-62703-227-8_17. Methods Mol Biol. 2013. PMID: 23325650

2

Intraoperative blood transfusion does not impact overall and recurrence-free survival after curative hepatectomy for hepatocellular carcinoma: A propensity-score-matched and inverse probability of treatment-weighted study.

Tan LLY, Chew VTW, Syn N, Tan EK, Koh YX, Teo JY, Cheow PC, Jeyaraj PR, Chow PKH, Chan CY, Chung AYF, Ooi LLPJ, Goh BKP. Tan LLY, et al. J Surg Oncol. 2023 Mar;127(4):598-606. doi: 10.1002/jso.27141. Epub 2022 Nov 10. J Surg Oncol. 2023. PMID: 36354172

3

Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients.

Chew V, Tow C, Teo M, Wong HL, Chan J, Gehring A, Loh M, Bolze A, Quek R, Lee VK, Lee KH, Abastado JP, Toh HC, Nardin A. Chew V, et al. J Hepatol. 2010 Mar;52(3):370-9. doi: 10.1016/j.jhep.2009.07.013. Epub 2009 Aug 3. J Hepatol. 2010. PMID: 19720422

4

Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma.

Chew V, Chen J, Lee D, Loh E, Lee J, Lim KH, Weber A, Slankamenac K, Poon RT, Yang H, Ooi LL, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado JP. Chew V, et al. Gut. 2012 Mar;61(3):427-38. doi: 10.1136/gutjnl-2011-300509. Epub 2011 Sep 19. Gut. 2012. PMID: 21930732 Free PMC article.

5

Immune predictors of cancer progression.

Toh B, Chew V, Dai X, Khoo K, Tham M, Wai LE, Hubert S, Velumani S, Zhi L, Huang C, Abastado JP. Toh B, et al. Among authors: chew v. Immunol Res. 2012 Sep;53(1-3):229-34. doi: 10.1007/s12026-012-8288-4. Immunol Res. 2012. PMID: 22407576 Review.

6

Immune microenvironment in tumor progression: characteristics and challenges for therapy.

Chew V, Toh HC, Abastado JP. Chew V, et al. J Oncol. 2012;2012:608406. doi: 10.1155/2012/608406. Epub 2012 Aug 8. J Oncol. 2012. PMID: 22927846 Free PMC article.

7

Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients.

Chew V, Tow C, Huang C, Bard-Chapeau E, Copeland NG, Jenkins NA, Weber A, Lim KH, Toh HC, Heikenwalder M, Ng IO, Nardin A, Abastado JP. Chew V, et al. J Natl Cancer Inst. 2012 Dec 5;104(23):1796-807. doi: 10.1093/jnci/djs436. Epub 2012 Nov 29. J Natl Cancer Inst. 2012. PMID: 23197495 Free PMC article.

8

Immunomodulation of the tumor microenvironment by Toll-like receptor-3 (TLR3) ligands.

Chew V, Abastado JP. Chew V, et al. Oncoimmunology. 2013 Apr 1;2(4):e23493. doi: 10.4161/onci.23493. Oncoimmunology. 2013. PMID: 23734310 Free PMC article.

9

Transposon mutagenesis identifies genes driving hepatocellular carcinoma in a chronic hepatitis B mouse model.

Bard-Chapeau EA, Nguyen AT, Rust AG, Sayadi A, Lee P, Chua BQ, New LS, de Jong J, Ward JM, Chin CK, Chew V, Toh HC, Abastado JP, Benoukraf T, Soong R, Bard FA, Dupuy AJ, Johnson RL, Radda GK, Chan EC, Wessels LF, Adams DJ, Jenkins NA, Copeland NG. Bard-Chapeau EA, et al. Among authors: chew v. Nat Genet. 2014 Jan;46(1):24-32. doi: 10.1038/ng.2847. Epub 2013 Dec 8. Nat Genet. 2014. PMID: 24316982 Free PMC article.

10

TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.

Ho V, Lim TS, Lee J, Steinberg J, Szmyd R, Tham M, Yaligar J, Kaldis P, Abastado JP, Chew V. Ho V, et al. Among authors: chew v. Oncotarget. 2015 Sep 29;6(29):27252-66. doi: 10.18632/oncotarget.4583. Oncotarget. 2015. PMID: 26287667 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

78 results

Search Page